Disentangling Astra/Oxford vaccine data (it's a messy trial/ data presentation):
Efficacy after 1st dose overall: 52.69% (95%CI 40.52-62.37)
108 v 227 cases/10k cohorts
Subgroup analysis from 3 weeks after 1st dose until 2nd dose or 12 weeks: 73.00% (48.79-85.76)
12 v 44/8k
1/
Efficacy after 1st dose overall: 52.69% (95%CI 40.52-62.37)
108 v 227 cases/10k cohorts
Subgroup analysis from 3 weeks after 1st dose until 2nd dose or 12 weeks: 73.00% (48.79-85.76)
12 v 44/8k
1/
Overall vaccine efficacy with 2 completed doses: 70.42% (95%CI 58.84-80.63)
30 v 101 cases/5.8k cohorts
0 hospitalised and 0 severe disease in full vaccine cohort
For 1 dose subgroup only 2 hospitalisations (day 1 and 10 post vaccine when no immunity conferred), 0 severe
2/
30 v 101 cases/5.8k cohorts
0 hospitalised and 0 severe disease in full vaccine cohort
For 1 dose subgroup only 2 hospitalisations (day 1 and 10 post vaccine when no immunity conferred), 0 severe
2/
The trial is limited by the variability in administration of the second dose between 4 to 26 weeks.
Higher antibody titres were seen when delaying 2nd dose to 12 weeks
Only 5.9% of trial were over 65, and they tended to be in the early 2nd dose category
3/
Higher antibody titres were seen when delaying 2nd dose to 12 weeks
Only 5.9% of trial were over 65, and they tended to be in the early 2nd dose category
3/
No significance between half and full dosing of 1st dose survived closer scrutiny
Likely was artifactual from the half dosing mistake subgroup receiving 2nd dose much later
Likely was artifactual from the half dosing mistake subgroup receiving 2nd dose much later
• • •
Missing some Tweet in this thread? You can try to
force a refresh
